AKR1C3 expression correlates with PR-104A sensitivity in primary ALL cells. (A) Mononuclear cells purified from BCP-ALL (solid line) and T-ALL (broken line) patients were treated with PR-104A in coculture with MSC-hTERT cells in a dose response. Cells were stained with 7AAD 24 hours following treatment and percentages of live cells are shown relative to vehicle treatment. (B) Proportion of live cells after treatment with 50 μM PR-104A for 24 hours for BCP-ALL and T-ALL subtypes. (C) RT-qPCR expression of AKR1C3 in patient cells relative to ALL-8 xenograft control. (D) Correlation of AKR1C3 expression and sensitivity to 50 μM PR-104A in BCP-ALL (gray) and T-ALL (black) patient samples. Results shown are the mean of 2 biological repeats. *P < .05; **P ≤ .005 by Mann-Whitney U test.